Volume 9, Issue 2 (5-2021)
Jorjani Biomed J 2021, 9(2): 27-35 |
Back to browse issues page
1- Department of Microbiology and Microbial Biotechnology, Shahid Beheshti University, Tehran, Iran
2- Nano Electronic Center of Excellence, Nano Bio Electronic Devices Lab, School of Electrical and Computer Engineering, University of Tehran, Tehran, Iran
3- Department of Microbiology and Microbial Biotechnology, Shahid Beheshti University, Tehran, Iran , N_soleimani@sbu.ac.ir
2- Nano Electronic Center of Excellence, Nano Bio Electronic Devices Lab, School of Electrical and Computer Engineering, University of Tehran, Tehran, Iran
3- Department of Microbiology and Microbial Biotechnology, Shahid Beheshti University, Tehran, Iran , N_soleimani@sbu.ac.ir
Abstract: (2938 Views)
Background and Objective: Cancer immunotherapy combined with other common treatments can be an effective way to overcome cancerous cells. The purpose of this study was to investigate the effect of Freund Adjuvant on breast cancer in the BALB/c model of mice.
Material and Methods: Twenty female inbred 6–7-week-old- BALB/c mice were randomly divided into two groups of Test and Control, each containing 10 mice. Breast cancer was induced by injecting106 4T1 cells into the right flank region of mice. After the tumors were palpable; animals were immunized three times by intraperitoneal (IP) injection of Freund adjuvant in the test group and phosphate buffered saline (PBS) in the control group at same condition. During the study; tumor growth, body weight, and survival percentages in mice were measured by using the caliper method, and mortalities were recorded. Results were tabulated using Excel, and Graphpad Prism Version 8. Data were analyzed using One-Way ANOVA and T-test and the significance level for statistical tests was considered p≤0.05.
Results: The results showed that tumor mice given Freund Adjuvant had a significant reduction in tumor size compared to the control group (P=0.01) and no significant weight difference was observed between the two groups (P=0.4). Furthermore, Kaplan Meier showed that the survival of the mice in the Freund Adjuvant group was significantly increased compared to the control group (P=0.009).
Conclusion: This study showed that Freund Adjuvant may play an important role in improving the function of the immune system for cancer immunotherapy.
Material and Methods: Twenty female inbred 6–7-week-old- BALB/c mice were randomly divided into two groups of Test and Control, each containing 10 mice. Breast cancer was induced by injecting106 4T1 cells into the right flank region of mice. After the tumors were palpable; animals were immunized three times by intraperitoneal (IP) injection of Freund adjuvant in the test group and phosphate buffered saline (PBS) in the control group at same condition. During the study; tumor growth, body weight, and survival percentages in mice were measured by using the caliper method, and mortalities were recorded. Results were tabulated using Excel, and Graphpad Prism Version 8. Data were analyzed using One-Way ANOVA and T-test and the significance level for statistical tests was considered p≤0.05.
Results: The results showed that tumor mice given Freund Adjuvant had a significant reduction in tumor size compared to the control group (P=0.01) and no significant weight difference was observed between the two groups (P=0.4). Furthermore, Kaplan Meier showed that the survival of the mice in the Freund Adjuvant group was significantly increased compared to the control group (P=0.009).
Conclusion: This study showed that Freund Adjuvant may play an important role in improving the function of the immune system for cancer immunotherapy.
Keywords: Breast Neoplasms [MeSH], Immunotherapy [MeSH], Freund's Adjuvant [MeSH], Animal model [MeSH]
Full-Text [PDF 599 kb]
(1027 Downloads)
| | Full-Text (HTML) (882 Views)
Immunotheray is stimulating body’s own immune system to work strongly or smartly to attack on cancer cells. Freund Adjuvant can be effective in immunotherapy for cancer by stimulating immune cells such as dendritic cells and T-cells and increasing the secretion of IFN-γ and other cytokines.
Type of Article: Original article |
Subject:
Basic Medical Sciences
Received: 2021/03/23 | Accepted: 2021/06/7 | Published: 2021/06/20
Received: 2021/03/23 | Accepted: 2021/06/7 | Published: 2021/06/20
References
1. Houssami N, Hunter K. The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening. npj Breast Cancer. 2017; 3:12. [view at publisher] [DOI] [Google Scholar]
2. Al-Mahmood S, Sapiezynski J, Garbuzenko O.B, Minko T. Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Delivery and Translational Research. 2018; 8(5):1483-1507. [view at publisher] [DOI] [Google Scholar]
3. Bertucci F, Ng C.K.Y, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019; 569(7757):560-564. [view at publisher] [DOI] [Google Scholar]
4. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019; 321(3):288-300. [view at publisher] [DOI] [Google Scholar]
5. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. [view at publisher] [DOI] [Google Scholar]
6. Corrales L, Matson V, Flood B, et al. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 2017; 27(1):96-108. [view at publisher] [DOI] [Google Scholar]
7. Shihab I, Khalil B.A, Elemam N.M, et al. Understanding the Role of Innate Immune Cells and Identifying Genes in Breast Cancer Microenvironment. Cancers. 2020; 12(8): 2226. [view at publisher] [DOI] [Google Scholar]
8. Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy. Nature. 2019; 574(7776):45-56. [view at publisher] [DOI] [Google Scholar]
9. Huang H, Zhou J, Chen H, et al. The immunomodulatory effects of endocrine therapy in breast cancer. J Exp Clin Cancer Res. 2021; 40(1):19. [view at publisher] [DOI] [Google Scholar]
10. Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. The Journal of clinical investigation. 2016; 126(3):799-808. [DOI] [Google Scholar]
11. Bueno J. Bioprospecting and their Role in the Innovation of Vaccine Adjuvants: Mega Diversity as a Source of Competitiveness. J Microb Biochem Technol. 2017; 9(2):e130. [DOI] [Google Scholar]
12. Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER, et al. Adjuvant and carrier proteindependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Scientific reports. 2017; 7(1):40312. [view at publisher] [DOI] [Google Scholar]
13. Apostólico JdS, Lunardelli VAS, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: classification, modus operandi, and licensing. Journal of immunology research. 2016; 2016(6):1-16. [view at publisher] [DOI] [Google Scholar]
14. Bonam SR, Partidos CD, Halmuthur SKM, Muller S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends in pharmacological sciences. 2017; 38(9):771-93. [view at publisher] [DOI] [Google Scholar]
15. Wang Z-B, Xu J. Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery. Vaccines. 2020; 8(1):128. [view at publisher] [DOI] [Google Scholar]
16. Bastola R, Noh G, Keum T, et al. Vaccine adjuvants: smart components to boost the immune system. Archives of Pharmacal Research. 2017; 40(11):1238-1248. [view at publisher] [DOI] [Google Scholar]
17. Hajam I.A, Dar P.A, Won G, et al. Bacterial ghosts as adjuvants: mechanisms and potential. Vet Res. 2017; 48(1): 37. [view at publisher] [DOI] [Google Scholar]
18. Hawksworth D. Advancing Freund's and AddaVax Adjuvant Regimens Using CpG Oligodeoxynucleotides. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2018; 37(5):195-199. [view at publisher] [DOI] [Google Scholar]
19. Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Frontiers in Oncology. 2018; 8:227. [view at publisher] [DOI] [Google Scholar]
20. Tom JK, Albin TJ, Manna S, et al. Applications of Immunomodulatory Immune Synergies to Adjuvant Discovery and Vaccine Development. Trends in Biotechnology. 2019; 37(4):373-388. [view at publisher] [DOI] [Google Scholar]
21. Shi S, Zhu H, Xia X, et al. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine. 2019; 37(24):3167-3178. [view at publisher] [DOI] [Google Scholar]
22. Dewangan H.K, Singh S, Mishra R, Dubey R.K. A Review On Application Of Nanoadjuvant As Delivery System. International Journal of Applied Pharmaceutics. 2020; 12(4): 24-33. [DOI] [Google Scholar]
23. Nguyen A.T, Shiao S.L, McArthur H.L, et al. Advances in Combining Radiation and Immunotherapy in Breast Cancer. Clinical Breast Cancer. 2021; 21(2):143-152. [view at publisher] [DOI] [Google Scholar]
24. Fahrer AM. A proposal for a simple and inexpensive therapeutic cancer vaccine, Immunology and Cell Biology. 2012; 90(3):310-3. [view at publisher] [DOI] [Google Scholar]
25. Gottwein J.M, Blanchard T.G, Targoni O.S, et al. Protective Anti‐Helicobacter Immunity Is Induced with Aluminum Hydroxide or Complete Freund's Adjuvant by Systemic Immunization. The Journal of Infectious Diseases. 2001; 184(3):308-14. [view at publisher] [DOI] [Google Scholar]
26. Ikeda H, Old L.J, Schreiber R.D. The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002; 13(2):95-109. [view at publisher] [DOI] [Google Scholar]
27. Ebbinghaus C, Ronca R, Kaspar M, et al. Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy, International Journal of Cancer. 2005; 116(2):304-313. [view at publisher] [DOI] [Google Scholar]
28. García-Tuñón I, Ricote M, Ruiz A, et al. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer. 2007; 7:158. [view at publisher] [DOI] [Google Scholar]
29. Pollack KE, Meneveau MO, Melssen MM, et al. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. Journal for Immuno Therapy of Cancer. 2020; 8(1):e000544. [view at publisher] [DOI] [Google Scholar]
30. Slingluff CL, Petroni GR, Olson WC, et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009; 15(22):7036-44. [view at publisher] [DOI] [Google Scholar]
31. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005; 175(9):6169-76. [DOI] [Google Scholar]
32. Kenter GG, Welters MJP, Valentijn ARPM, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009; 361:1838-47. [view at publisher] [DOI] [Google Scholar]
33. Melssen M.M, Petroni G.R, Chianese-Bullock K.A, et al. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. J. immunotherapy cancer. 2019; 7(1):163. [view at publisher] [DOI] [Google Scholar]
34. Marzo A.L, Kinnear B.F, Lake R.A, et al. Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. Journal of Immunology. 2000; 165(11):6047-6055. [view at publisher] [DOI] [Google Scholar]
35. Assudani D.P, Horton R.B.V, Mathieu M.G, McArdle S.E.B, Rees R.C. The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother. 2007; 56(1):70-80. [view at publisher] [DOI] [Google Scholar]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |